Flanders Investment and Trade Names Legend Biotech Newcomer of the Year
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, was named Newcomer of the Year at the tenth annual Foreign Investment Trophy ceremony hosted by Flanders Investment & Trade (FIT).
Flanders Investment and Trade is a Flemish government organization that facilitates investment projects in Flanders, a northern region of Belgium, and supports Flemish companies. The Foreign Investment Trophy recognizes international firms with investment projects in Flanders, and FIT’s Newcomer of the Year award is conferred upon organizations who have recently embarked on substantial investment projects in the region.
Legend Biotech earned the honor for its joint investment in a state-of-the-art manufacturing facility in Flanders with Janssen Pharmaceutica N.V. (Janssen). The cell therapy facility is the first-ever cell therapy manufacturing site located in Flanders, and it will serve as a regional hub for the companies’ cell therapy production for patients in Europe, the Middle East and Africa.
The 26,000-square-meter manufacturing hub is part of Legend’s collaboration with Janssen to advance the manufacturing of ciltacabtagene autoleucel (cilta-cel), a B cell maturation antigen-directed CAR-T treatment being evaluated for the treatment of relapsed or refractory multiple myeloma by the European Medicines Agency. In April 2019, cilta-cel was granted PRIME (Priority Medicines) designation. PRIME offers enhanced interaction and early dialogue with the developers of promising medicines to optimize drug development plans and speed up the evaluation of cutting-edge, scientific advances that target a high unmet medical need.
The European manufacturing hub is anticipated to come on-line in 2023 and will be managed by Legend Biotech.
As he accepted the award in Belgium, Ying Huang, PhD, CEO and CFO of Legend Biotech, said: “This award is special recognition of our investment in Flanders, one of Europe’s most exciting biotechnology hubs. The Newcomer of the Year award marks how far we’ve come in since Legend was established to apply cell therapy to rare and uncommon diseases. We look forward to advancing that goal and to playing a meaningful role in the Ghent ecosystem for years to come.”
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.
Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.
About Flanders Investment & Trade
Flanders Investment & Trade (FIT) actively promotes sustainable international business in Flanders as a key element of the region’s socio-economic development. FIT accomplishes this by supporting Flanders-based companies in their international business ventures and by attracting foreign investors. FIT assists businesses across Flanders in their international endeavors and provides custom advice and support. Companies can call on the agency’s local and international networks of contacts, while FIT also offers financial support and information about the financial incentives available.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives; statements relating to CARVYKTI™, including Legend Biotech’s expectations for CARVYKTI™, such as Legend Biotech’s manufacturing and commercialization expectations for CARVYKTI™ and the potential effect of treatment with CARVYKTI™; statements about submissions for cilta-cel to, and the progress of such submissions with, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Chinese Center for Drug Evaluation of National Medical Products Administration (CDE) and other regulatory authorities; the anticipated timing of, and ability to progress, clinical trials, including patient enrollment; the submission of Investigational New Drug (IND) applications to, and maintenance of such applications with, regulatory authorities; the ability to generate, analyze and present data from clinical trials; and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general public pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the “Risk Factors” section of the Legend Biotech’s Annual Report filed with the Securities and Exchange Commission on April 2, 2021. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005185/en/
Contact information
Press:
Tina Carter, Corporate Communications Lead, Legend Biotech
tina.carter@legendbiotech.com
(908) 331-5025
Investors:
Joanne Choi, Senior Manager of Investor Relations, Legend Biotech
Joanne.choi@legendbiotech.com
Crystal Chen, Manager of Investor Relations, Legend Biotech
crystal.chen@legendbiotech.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Revolutionize Brand Engagement: MSquared Puts Interoperability Center Stage in MLB’s Virtual Ballpark!26.9.2024 22:48:00 CEST | Press Release
Solving the Interoperability Challenge MSquared’s demonstration is the first major showcase of how it has solved the technical challenges of metaverse interoperability. The integration of the Metaverse Markup Language (MML) lies at the heart of this success, offering a revolutionary way to define interactive 3D content that can seamlessly run across different virtual spaces and engines. Additionally, M² has developed a secure digital rights management and moderation system that allows IP owners and consumers to have appropriate protections as content moves freely between worlds. “MSquared has systematically overcome the challenges of interoperability - from ownership to standardized visualizations and secure asset storage,” said Rob Whitehead, Chief Product Officer of Improbable. “Our technology safeguards intellectual property and brand integrity across diverse virtual environments, ensuring seamless and secure experiences.” Elevate Your Brand in the Metaverse This milestone event in
Grid Dynamics Expands Global Footprint with JUXT Acquisition, Strengthening Expertise in Banking and Financial Services26.9.2024 22:05:00 CEST | Press Release
Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) (Grid Dynamics), a leading provider of technology consulting, platform and product engineering, AI, and digital engagement services, today announces its acquisition of JUXT, a UK-based provider of software engineering services specializing in data-intensive information systems for banking and other financial institutions, with a particular focus on risk platforms, structured notes, equity derivatives, and financial reporting. With this acquisition, Grid Dynamics adds significant expertise and capabilities to better serve enterprise clients in the financial services industry. Founded in 2013, JUXT is known for delivering complex end-to-end solutions, from design and user experience, to deep functionality and ongoing managed services. Their specializations in mission-critical platforms and products for leading banks and financial institutions make them a strategically important addition to Grid Dynamics, especially as global demand for reliable
BM3EAC Corp. 2024 Semi-Annual Report26.9.2024 20:58:00 CEST | Press Release
BM3EAC Corp. (the “Company”), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2024 to 30 June 2024. The semi-annual report can be downloaded from the Company’s website via the following link: https://www.BrigadeM3EAC.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announ
UCC Holding Ranked 42 nd in ENR’s Top International Contractors26.9.2024 20:32:00 CEST | Press Release
Urbacon Holding, a leader in energy, concessions, and construction, announced its ranking as the 42nd top international contractor for 2024, according to Engineering News-Record (ENR). The company celebrated this achievement during the ConteQ Expo 2024 in Qatar, where it participated as the event's official sponsor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240926450701/en/ UCC Holding Ranked 42nd in ENR’s Top International Contractors (Photo: AETOSWire) The event brought together UCC Holding’s Board of Directors and senior management, who emphasized the company’s ongoing efforts to integrate advanced construction technologies into its operations. During the expo, UCC Holding introduced three innovative construction methods: 3D construction printing, concrete modular construction, and steel structure modular construction. These technologies are already being incorporated into UCC’s future projects, including a series of
Sinopec Awarded Best Environmental Protection Case at First Sino-European Corporate ESG Best Practice Conference26.9.2024 19:06:00 CEST | Press Release
The ESG case from China’s Sinopec, titled “Empowering Green Development, Co-Creating a Zero-Carbon Future,” stood out from dozens of entries and was awarded the Best Case in the Environmental Protection category at the first Sino-European Corporate ESG Best Practice Conference held in Frankfurt, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240926903754/en/ An ESG case from China’s Sinopec was awarded the Best Case in the Environmental Protection category at the first Sino-European Corporate ESG Best Practice Conference held in Frankfurt, Germany. (Photo: Business Wire) Walter Döring, Chairman of German World Market Leaders Association, on behalf of the event's organizing committee, announced the results. He stated, “Sinopec has demonstrated exceptional practical value in environmental protection. Through its comprehensive environmental management system and innovative technological means, as well as the use of cle
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom